Hamdy Abdel Azim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hamdy Abdel Azim has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Loay Kassem
Department of Clinical Oncology Cairo University Cairo Egypt
3 shared publications- Abdrabou N. Mashhour
Faculty Of Medicine, Cairo University, Cairo, Egypt
2 shared publications - Ahmed Abdelaziz Abozeid
Department of Surgery, El Demerdash Hospital, Ain Shams University, Abbasiya, 11566 Cairo, Egypt
2 shared publications - Ahmed Farag
General Surgery, Faculty of Medicine, Cairo University, Giza, Egypt
2 shared publications - Kyrillus S. Shohdy
School of Cancer Sciences University of Glasgow Glasgow UK
2 shared publications - Loay Kassem
Clinical Oncology Department, Faculty of medicine, Cairo University, Cairo, Egypt
2 shared publications
Latest Publications
- Open Access
- 6 October 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (13) , 2304-2306
Homologous Recombination Deficiency Testing in Women With Ovarian Cancer: An Egyptian Multicentre Study
- 6 October 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (13) , 2304-2306
Open AccessHomologous Recombination Deficiency Testing in Women With Ovarian Cancer: An Egyptian Multicentre Study
- Open Access
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer
Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.
Open AccessBreast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer
Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.
- 23 December 2019
- Published by Hindawi Limited in The Breast Journal
- Vol. 26 (1) , 69-80
Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020
Compared with other breast cancer subtypes, patients with triple‐negative breast cancer (TNBC), and irrespective to their disease stage, were always recognized to have the worst overall survival data. Although this does not seem different at the present time, yet the last few years have witnessed many breakthrough genomic and molecular findings, that could dramatically improve our understanding of the biological complexity of TNBC. Based on genomic analyses, it was consistently evident that TNBC comprises a heterogeneous group of cancers, which have numerous diverse molecular aberrations. This—in return—has provided a platform for a new generation of clinical trials using many innovative therapies, directed against such novel targets. At the present time, two PARP inhibitors and one anti‐PD‐L1 monoclonal antibody (in combination with chemotherapy) have been approved in certain subpopulations of metastatic TNBC (mTNBC) patients, which have finally brought this disease into the era of personalized medicine. In the current review, we will explore the genomic landscape of TNBC, through which many actionable targets were graduated. We will also discuss the results of the key—practice changing—clinical studies, and some upcoming personalized treatment options for patients with mTNBC, that may be clinically adopted in the near future.
- 23 December 2019
- Published by Hindawi Limited in The Breast Journal
- Vol. 26 (1) , 69-80
Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020
Compared with other breast cancer subtypes, patients with triple‐negative breast cancer (TNBC), and irrespective to their disease stage, were always recognized to have the worst overall survival data. Although this does not seem different at the present time, yet the last few years have witnessed many breakthrough genomic and molecular findings, that could dramatically improve our understanding of the biological complexity of TNBC. Based on genomic analyses, it was consistently evident that TNBC comprises a heterogeneous group of cancers, which have numerous diverse molecular aberrations. This—in return—has provided a platform for a new generation of clinical trials using many innovative therapies, directed against such novel targets. At the present time, two PARP inhibitors and one anti‐PD‐L1 monoclonal antibody (in combination with chemotherapy) have been approved in certain subpopulations of metastatic TNBC (mTNBC) patients, which have finally brought this disease into the era of personalized medicine. In the current review, we will explore the genomic landscape of TNBC, through which many actionable targets were graduated. We will also discuss the results of the key—practice changing—clinical studies, and some upcoming personalized treatment options for patients with mTNBC, that may be clinically adopted in the near future.
- Open Access
- 1 November 2018
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 5, 109-119
Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
Background: Phase II trials found that tegafur–uracil (UFT) is an effective drug in hepatocellular carcinoma (HCC), while preclinical data suggested that its combination with sorafenib may have a promising activity. Our Phase II randomized trial aimed to evaluate efficacy and tolerability of sorafenib plus UFT vs sorafenib in advanced HCC. Methods: Patients with advanced HCC, with no prior systemic therapy, were randomized to receive either UFT at 125 mg/m2 twice daily for 4 out of 5 weeks plus sorafenib at 400 mg twice daily (arm 1) or single agent sorafenib at 400 mg twice daily (arm 2). Primary end point was time to progression (TTP). Results: Between March 2012 and March 2014, 76 eligible patients – out of 143 preplanned – were randomized. The study was terminated early because of futility. This is the final analysis of the study, after a median follow-up of 10.2 months and death of 86% of randomized patients (n=64). Median TTP was 7.5 months and 8.2 months in arms 1 and 2 respectively (HR: 1.07; 95% CI, 0.52–2.22; P=0.855), while the median overall survival was 8.2 months and 10.5 months respectively (HR: 1.58; 95% CI: 0.90–2.76, P=0.112). Nine patients (25%) in the combination arm discontinued treatment because of toxicity vs eight patients (21.1%) in the sorafenib monotherapy arm (P=0.899). Conclusion: In patients with advanced HCC, adding UFT to sorafenib is feasible, but it did not improve efficacy outcome over sorafenib monotherapy.
- 1 November 2018
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 5, 109-119
Open AccessSorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
Background: Phase II trials found that tegafur–uracil (UFT) is an effective drug in hepatocellular carcinoma (HCC), while preclinical data suggested that its combination with sorafenib may have a promising activity. Our Phase II randomized trial aimed to evaluate efficacy and tolerability of sorafenib plus UFT vs sorafenib in advanced HCC. Methods: Patients with advanced HCC, with no prior systemic therapy, were randomized to receive either UFT at 125 mg/m2 twice daily for 4 out of 5 weeks plus sorafenib at 400 mg twice daily (arm 1) or single agent sorafenib at 400 mg twice daily (arm 2). Primary end point was time to progression (TTP). Results: Between March 2012 and March 2014, 76 eligible patients – out of 143 preplanned – were randomized. The study was terminated early because of futility. This is the final analysis of the study, after a median follow-up of 10.2 months and death of 86% of randomized patients (n=64). Median TTP was 7.5 months and 8.2 months in arms 1 and 2 respectively (HR: 1.07; 95% CI, 0.52–2.22; P=0.855), while the median overall survival was 8.2 months and 10.5 months respectively (HR: 1.58; 95% CI: 0.90–2.76, P=0.112). Nine patients (25%) in the combination arm discontinued treatment because of toxicity vs eight patients (21.1%) in the sorafenib monotherapy arm (P=0.899). Conclusion: In patients with advanced HCC, adding UFT to sorafenib is feasible, but it did not improve efficacy outcome over sorafenib monotherapy.
- 11 July 2018
- Published by Hindawi Limited in The Breast Journal
- Vol. 24 (4) , 459-461
Treatment of HER2-positive early breast cancer: How to best balance efficacy and toxicity?
- 11 July 2018
- Published by Hindawi Limited in The Breast Journal
- Vol. 24 (4) , 459-461
Treatment of HER2-positive early breast cancer: How to best balance efficacy and toxicity?
- Open Access
- 1 April 2016
- Published by Elsevier in Translational Oncology
- Vol. 9 (2) , 114-123
Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer
- 1 April 2016
- Published by Elsevier in Translational Oncology
- Vol. 9 (2) , 114-123
Open AccessAnalysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer
- 30 January 2016
- Published by Elsevier in International Journal of Surgery
- Vol. 27, 147-150
TNMF versus TNM in staging of colorectal cancer
- 30 January 2016
- Published by Elsevier in International Journal of Surgery
- Vol. 27, 147-150
TNMF versus TNM in staging of colorectal cancer
- 23 September 2015
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 7 (4) , 215-223
Potential Therapeutic Targets in Triple Negative Breast Cancer
- 23 September 2015
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 7 (4) , 215-223
Potential Therapeutic Targets in Triple Negative Breast Cancer
- 1 September 2015
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 16 (3-4) , 113-115
Reporting of the circumferential tumour margin involvement and preoperative levels of carcinoembryonic antigen as prognostic risk factors in colorectal cancer patients
- 1 September 2015
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 16 (3-4) , 113-115
Reporting of the circumferential tumour margin involvement and preoperative levels of carcinoembryonic antigen as prognostic risk factors in colorectal cancer patients